The Medical House and Dr Reddy's enter licensing deal
This article was originally published in Scrip
The Medical House (TMH), a specialist in drug delivery, has signed a non-exclusive development, licensing and supply agreement withDr Reddy's Laboratories. Under the terms of deal, TMH will customise its proprietary, patented ASI disposable auto-injector device technology as per an agreed specification. This technology allows injections to be easily and safely undertaken by patients or other non-clinicians and is suitable for both elective therapies and emergency situations. Dr Reddy's will combine the customised auto-injector device with an undisclosed drug, to create a new self-injectable product. The agreement covers an initial five-year supply term within the US, EU and Canada, with an option for Dr Reddy's to extend the deal to the rest of the world on mutually agreed terms. The development costs associated with customisation will be paid to TMH in addition to reimbursement of all agreed external costs. First commercial supply of the customised ASI device is expected to be in 2009-10 and TMH will receive a technology access fee during the term of the agreement. TMH's projected revenue over the first five years is estimated at £5 million.
You may also be interested in...
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.